Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devic…
Medical - Devices
US, Marlborough [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$2,239,210,000
d
cs
10% Holder
|
01/03/25 |
S
|
96,890,000 x $89.86 = $8,706,535,400.00 |
Footnotes
#1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
#2 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
#3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.52 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
|||
|
$284,540,000
d
cs
10% Holder
|
01/03/25 |
S
|
71,520,000 x $89.86 = $6,426,787,200.00 |
Footnotes
#1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
#2 Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available.
#3 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
#4 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.523 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
|||
|
$329,770,000
d
cs
10% Holder
|
01/03/25 |
S
|
23,420,000 x $89.86 = $2,104,521,200.00 |
Footnotes
#1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
#2 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
#3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
|||
|
$353,190,000
d
cs
10% Holder
|
01/02/25 |
S
|
41,190,000 x $90.02 = $3,707,923,800.00 |
Footnotes
#1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
#2 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
#3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
|||
|
$15,783,260,000
d
cs
10% Holder
|
01/01/25 |
M
|
571,210,000 x $0 = $0 |
Footnotes
#1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
|
|||
Get PRO Today
With PRO you will unlock 230 more insider transactions for Boston Scientific Corporation
Statistics
Sample Size: 235 Transactions
Sale (S)
11,329,480,000 Shares
18.30%
Buy (P)
0 Shares
0.00%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Brennan Daniel J. EVP and CFO
- Brown Vance R SVP, GC and Corp. Secretary
- Butcher Arthur C Director
- Carruthers Wendy EVP, Human Resources
- Dockendorff Charles J Director
- Fitzgerald Joseph Michael EVP & Group Pres, Cardiology
- Fujimori Yoshiaki Director
- Habiger David C Director
- Ludwig Edward J Director
- Mahoney Michael F Director
- Mega Jessica L Director
- Mirviss Jeffrey B. EVP&Pres, Periph Intervent
- Monson Jonathan SVP, Global Controller and CAO
- Morano Susan E Director
- O'Sullivan Miriam SVP, Chief HR Officer
- Pegus Cheryl Director
- Sorenson John Bradley EVP, Global Operations
- Sununu John E Director
- Thepaut Eric Francis Yves EVP & Pres, Eur, Mid-East, Afr
- Wichmann David S Director
- Woodworth Emily SVP, Global Controller and CAO
- Zane Ellen M Director
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Brennan Daniel J. EVP and CFO
- Brown Vance R SVP, GC and Corp. Secretary
- Butcher Arthur C Director
- Carruthers Wendy EVP, Human Resources
- Dockendorff Charles J Director
- Fitzgerald Joseph Michael EVP & Group Pres, Cardiology
- Fujimori Yoshiaki Director
- Habiger David C Director
- Ludwig Edward J Director
- Mahoney Michael F Director
- Mega Jessica L Director
- Mirviss Jeffrey B. EVP&Pres, Periph Intervent
- Monson Jonathan SVP, Global Controller and CAO
- Morano Susan E Director
- O'Sullivan Miriam SVP, Chief HR Officer
- Pegus Cheryl Director
- Sorenson John Bradley EVP, Global Operations
- Sununu John E Director
- Thepaut Eric Francis Yves EVP & Pres, Eur, Mid-East, Afr
- Wichmann David S Director
- Woodworth Emily SVP, Global Controller and CAO
- Zane Ellen M Director